IMMUNE DESIGN CORP.
IMMUNE DESIGN CORP. (IMDZ): 4 pipeline candidates. Updated within the last hour.
BioSniper Score
3-factor signal · derived from public data
N/A
0% dilution
Lead: Phase 3
4 candidates
N/A
N/A
A transparent, data-derived signal for IMMUNE DESIGN CORP.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$78.1M
Quarterly Burn
—
Runway
—
Revenue
$476K
Pipeline (4 candidates)
Frequently asked questions
How many drug candidates are in IMMUNE DESIGN CORP.'s pipeline?
IMMUNE DESIGN CORP. (IMDZ) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is IMMUNE DESIGN CORP.'s lead drug candidate?
IMMUNE DESIGN CORP.'s most advanced tracked candidate is ca21 (Preclinical) for Oncology.
Who is the CEO of IMMUNE DESIGN CORP.?
Carlos V. Paya, M.D. is the chief executive officer of IMMUNE DESIGN CORP. (IMDZ).
Get the full picture on IMMUNE DESIGN CORP.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.